SCHEMBL22052

SCHEMBL22052

CC(CCCC(=O)Cl)C(=O)Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 2/20 0.44
CA1 P00915 4/20 0.35
LTA4H P09960 1/20 0.35
CYP1A2 P05177 1/20 0.34
BLM P54132 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA4 P43681 1/20 0.33
NFKB1 P19838 1/20 0.31
GABRP O00591 2/20 0.30
GABRD O14764 2/20 0.30
GABRA1 P14867 2/20 0.30
GABRB1 P18505 2/20 0.30
GABRG2 P18507 2/20 0.30
GABRB3 P28472 2/20 0.30
GABRA5 P31644 2/20 0.30
GABRA3 P34903 2/20 0.30
GABRA2 P47869 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6666348 0.93 ALDH1A1 (0.48) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL494013 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL494900 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL3059308 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL495140 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL494087 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL495251 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL494185 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL495750 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H
SCHEMBL495948 0.91 ALDH1A1 (0.52) ALDH1A1TP53TSHRCA1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124472-B2 Myocardial regeneration promoting compounds, preparation method thereof, and pharmaceutical composition GENHEALTH PHARMA CO., LTD. (TW) 2021-09-21 US claimed
EP-3725763-A1 MYOCARDIAL REGENERATION PROMOTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND THEIR USE Genhealth Pharma Co., Ltd. (TW) 2020-10-21 EP claimed
US-20200317602-A1 MYOCARDIAL REGENERATION PROMOTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND THEIR USE GENHEALTH PHARMA CO., LTD. (TW) 2020-10-08 US claimed
CN-107503132-A A kind of method for being knitted fabric post processing 安徽宝源帽业有限公司 2017-12-22 CN claimed
CN-106700949-A Multifunctional polishing paste and preparation method and usage method thereof 安徽雷萨重工机械有限公司 2017-05-24 CN claimed
EP-0792873-A1 N-(Phenoxyalkyl) carboxamides and their use as antiarrhythmic agents American Cyanamid Company (US) 1997-09-03 EP claimed
EP-4735046-A1 BIOCONJUGATION SYSTEMS AND USES THEREOF Université de Tours (FR) 2026-05-06 EP disclosed
WO-2025003392-A1 BIOCONJUGATION SYSTEMS AND USES THEREOF UNIVERSITÉ DE TOURS (FR) 2025-01-02 WO disclosed
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-12-12 US disclosed
US-20240307517-A1 DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION FENTANYL-CONJUGATE VACCINE TO TREAT FENTANYL ADDICTION CORNELL UNIVERSITY (US) 2024-09-19 US disclosed
EP-3504267-B1 OLIGOESTERS COMPOSITIONS AND METHODS OF MAKING AND USING SAME KRATON CHEMICAL LLC (US) 2024-08-21 EP disclosed
EP-4408475-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS Københavns Universitet (DK) 2024-08-07 EP disclosed
EP-3635056-B1 LIGHT COLOR ROSIN ESTER COMPOSITIONS AND METHODS OF MAKING SAME KRATON POLYMERS LLC (US) 2024-04-10 EP disclosed
EP-0123543-B1 LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION AND USE AND COMPOSITIONS CONTAINING THEM MERCK FROSST CANADA INC. (CA) 1988-02-03 EP disclosed
US-4617371-A CHOLESTERIC Blumstein, Alexandre (US) 1986-10-14 US disclosed
US-4609744-A 4-oxo-benzopyran carboxylic acids MERCK FROSST CANADA INC. (CA) 1986-09-02 US disclosed
EP-0123543-A1 Leukotriene antagonists, their production and use and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-10-31 EP disclosed
US-4145516-A INCORPORATING A DIOL CONTAINING A KETONE CARBONYL THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 1979-03-20 US disclosed
US-4136100-A BLUE-VIOLET TO GREEN-BLUE DYEINGS ON CELLULOSE TEXTILES BASF AKTIENGESELLSCHAFT (DE) 1979-01-23 US disclosed
US-3940390-A Process for the production of 2,3,4,5,6,7-hexahydrocyclopenta-(3)-1,3-oxazine-2,4-dione compounds BAYER AKTIENGESELLSCHAFT (DT) 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317602-A1 MYOCARDIAL REGENERATION PROMOTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND THEIR USE TNNI3, TNNT2, MYLK2 ALDH1A1 220/4885TP53 4860/4885TSHR 3979/4885
US-20240408218-A1 CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS GLP1R, PRKAG1, GCGR ALDH1A1 3012/4885TP53 1836/4885TSHR 123/4885
US-11124472-B2 Myocardial regeneration promoting compounds, preparation method thereof, and pharmaceutical composition TNNI3, MYLK2, TNNT2 ALDH1A1 281/4885TP53 4857/4885TSHR 3875/4885
US-20240307517-A1 DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION FENTANYL-CONJUGATE VACCINE TO TREAT FENTANYL ADDICTION OPRK1, OPRM1, OPRD1 ALDH1A1 1976/4885TP53 4280/4885TSHR 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.